Loading…
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-46M | $-46M | $-39M | -48.9% | - | 7.8% |
| 2024 | $0M | $-43M | $-43M | $-31M | -35.8% | - | -9.5% |
| 2023 | $0M | $-47M | $-48M | $-28M | -33.5% | - | -1.0% |
| 2022 | $0M | $-48M | $-48M | $-24M | -33.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 50.99 | 55.74 | 52.80 | 51.37 |
| Research And Development | - | 37.92 | 43.72 | 41.84 | 37.59 |
| Selling General And Administration | - | 13.07 | 12.05 | 11.04 | 13.82 |
| Total Expenses | - | 50.99 | 55.74 | 52.80 | 51.37 |
| Operating Income | - | -50.99 | -55.74 | -52.80 | -51.37 |
| Total Operating Income As Reported | - | -50.99 | -55.76 | -52.88 | -51.41 |
| EBITDA | - | -47.62 | -46.54 | -43 | -46.38 |
| Normalized EBITDA | - | -46.72 | -46.50 | -43.19 | -46.04 |
| EBIT | - | -47.62 | -46.54 | -43 | -46.38 |
| Interest Income | - | 0.95 | 6.52 | 7.32 | 4.68 |
| Interest Expense | - | 0 | 0.96 | 0 | 0 |
| Net Interest Income | - | 0.95 | 5.56 | 7.32 | 4.68 |
| Other Non Operating Income Expenses | - | 3.32 | 2.72 | 2.29 | 0.65 |
| Other Income Expense | - | 2.42 | 2.68 | 2.48 | 0.32 |
| Interest Income Non Operating | - | 0.95 | 6.52 | 7.32 | 4.68 |
| Interest Expense Non Operating | - | 0 | 0.96 | 0 | 0 |
| Net Non Operating Interest Income Expense | - | 0.95 | 5.56 | 7.32 | 4.68 |
| Pretax Income | - | -47.62 | -47.50 | -43 | -46.38 |
| Tax Provision | 0.27 | 0.36 | 0.01 | 0 | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.19 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -47.98 | -47.50 | -43 | -46.38 |
| Net Income From Continuing And Discontinued Operation | - | -47.98 | -47.50 | -43 | -46.38 |
| Net Income From Continuing Operation Net Minority Interest | - | -47.98 | -47.50 | -43 | -46.38 |
| Net Income | - | -47.98 | -47.50 | -43 | -46.38 |
| Net Income Common Stockholders | - | -47.98 | -47.50 | -43 | -46.38 |
| Net Income Including Noncontrolling Interests | - | -47.98 | -47.50 | -43 | -46.38 |
| Normalized Income | - | -47.26 | -47.46 | -43.19 | -46.04 |
| Diluted NI Availto Com Stockholders | - | -47.98 | -47.50 | -43 | -46.38 |
| Basic Average Shares | - | 76.91 | 79.79 | 83.47 | 85.29 |
| Diluted Average Shares | - | 76.91 | 79.79 | 83.47 | 85.29 |
| Total Unusual Items | - | -0.90 | -0.04 | 0.19 | -0.33 |
| Total Unusual Items Excluding Goodwill | - | -0.90 | -0.04 | 0.19 | -0.33 |
| Gain On Sale Of Security | - | -0.90 | -0.04 | 0.19 | -0.33 |
| General And Administrative Expense | - | 13.07 | 12.05 | 11.04 | 13.82 |
| Other Gand A | - | 13.07 | 12.05 | 11.04 | 13.82 |
| Other Operating Expenses | -0.05 | - | -0.02 | -0.08 | -0.04 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp.this co. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Eledon Pharmaceuticals, Inc. | ELDN | $278M | -6.09 | 3.43 | -56.3% | -3.08 |
| Entrada Therapeutics, Inc. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE |
| - |
| - |
| - |
| - |
| $258M |
| -1.89 |
| 1.24 |
| -65.8% |
| -2.14 |
| Nuvectis Pharma, Inc. | NVCT | $257M | -9.70 | 13.93 | -143.6% | - |
| Codexis, Inc. | CDXS | $255M | -5.79 | 5.04 | -87.0% | -8.18 |
| Sight Sciences, Inc. | SGHT | $250M | -6.51 | 3.91 | -60.1% | -6.07 |
| Protara Therapeutics, Inc. | TARA | $248M | -4.32 | 1.26 | -29.2% | -3.14 |
| Peer Median | - | -5.94 | 3.67 | -58.2% | -3.08 | |